- What the Clinical Biochemical Genetics Credential Is
- Who Issues It and Where the Official Rules Live
- How the Blueprint Divides the Exam
- The Heavyweight Domains: Amino Acids, Lipids, Organic Acids, Lysosomes
- Mid-Weight Content: Carbohydrates, Cofactors, Mitochondria, Laboratory
- Small Domains That Still Appear
- Exam Timing and Scheduling Mechanics
- What Is Not Published in the Supplied Sources
- Sequencing Your Preparation Around the Blueprint
- Where This Credential Fits in a Career
- Frequently Asked Questions
- CBG here means Clinical Biochemical Genetics, certified through the American Board of Medical Genetics and Genomics (ABMGG).
- The blueprint has fifteen content categories; Amino acids carries the largest published weight at about 15%.
- Biochemical specialties are offered in odd years, and the next exam is identified as August 2027.
- Published percentages sum to 102% because of a source discrepancy; they are approximate, not normalized.
What the Clinical Biochemical Genetics Credential Is
Clinical Biochemical Genetics is a board-level specialty centered on the laboratory diagnosis and interpretation of inborn errors of metabolism. The work spans the biochemical signatures of disease: amino acid profiles, organic acid patterns, acylcarnitine findings, enzyme assays, and the clinical correlations that connect an abnormal result to a specific disorder. If you are still orienting yourself, the explainers on what CBG certification is and what CBG stands for cover the basics, and this article focuses on the credential itself and how its content is organized.
Be careful with the acronym. "CBG" is shared by several unrelated credentials in other fields. Everything on this page refers only to the biochemical genetics certification administered through ABMGG, and nothing here should be read as describing any other credential that happens to use the same letters.
Who Issues It and Where the Official Rules Live
The certifying body is the American Board of Medical Genetics and Genomics. The primary documents a candidate should read directly are:
- The ABMGG initial certification page for content outlines and blueprints
- The Biochemical Genetics Blueprint and Content Codes document, effective August 2025
- The ABMGG announcement of the 2027 certification exam window
- The ABMGG news item on the transition to an annual certifying examination schedule
One wrinkle worth knowing: the ABMGG index page references 2026 outlines, while the blueprint document supplied for this article is the one effective August 2025. When two documents seem to disagree, treat the board's own current publication as authoritative and re-check it before you commit to a study plan. Eligibility questions, such as training pathways and prerequisites, are handled in the separate guide to CBG requirements and how to qualify.
How the Blueprint Divides the Exam
The blueprint lists fifteen content categories with approximate percentages. These are preserved exactly as published, and they total 102% because of a discrepancy in the source document. They should be read as relative emphasis, not as a precise question count per category.
| Domain | Approx. Weight |
|---|---|
| Amino acids | 15% |
| Lipids | 13% |
| Organic acids | 12% |
| Lysosomes | 12% |
| Carbohydrates | 10% |
| Laboratory | 8% |
| Cofactors | 7% |
| Mitochondria | 7% |
| Peroxisomes | 3% |
| Purines and pyrimidines | 3% |
| Transport | 3% |
| Metals | 3% |
| Other disease category | 3% |
| Neurotransmitters | 2% |
| Creatine | 1% |
The top four categories (Amino acids, Lipids, Organic acids, and Lysosomes) account for roughly half of the published weight. For a category-by-category walkthrough, see the full guide to all 15 CBG content areas.
The Heavyweight Domains: Amino Acids, Lipids, Organic Acids, Lysosomes
Amino acids (about 15%)
This is the largest single category and it rewards pattern recognition across analytes, not isolated memorization.
- PKU and hyperphenylalaninemia, including how cofactor defects enter the differential
- Tyrosinemias and glycine encephalopathy/hyperglycinemia
- MSUD and disorders of branched-chain amino acids
- Homocystinuria and disorders of sulfur amino acids and re-methylation
- Urea cycle defects, plus a catch-all of other conditions including serine disorders
Lipids (about 13%)
Three blocks define this category, and fatty acid oxidation is the one most candidates expect.
- Fatty acid oxidation disorders across short-, medium-, and long-chain defects, plus multiple acyl-CoA dehydrogenase deficiency (GA2)
- Hyperlipidemias, including Tangier disease
- Cholesterol metabolism disorders such as Smith-Lemli-Opitz and Niemann-Pick C, along with bile acid disorders
Organic acids (about 12%)
Here the testing logic is usually profile interpretation: which metabolites accumulate, and what does that point to?
- Methylmalonic acidemia (excluding cobalamin defects) and propionic acidemia
- 3-MCC deficiency and other C5OH-related disorders
- Isovaleric acidemia (IVA) and other C5-related disorders
- Glutaric acidemia type I
- Disorders of ketone body metabolism, including HMG-CoA lyase and SCOT
- Other conditions including glutathione synthetase deficiency, ECHS1, and 3-methylglutaconic aciduria outside type 1
Lysosomes (about 12%)
Expect enzyme, substrate, and phenotype relationships across a long list of storage disorders.
- Mucopolysaccharidoses, including Types I, II, III, IV, VI, and VII
- Sphingolipidoses: Gaucher, Fabry, GM2 gangliosidoses (Tay-Sachs and variants, Sandhoff), Krabbe, Niemann-Pick types A and B, GM1 gangliosidosis
- Multiple enzyme deficiencies such as mucolipidoses ML-II and ML-III and multiple sulfatase deficiency
- Other lysosomal conditions including Pompe, cystinosis, and NCL
Note the careful boundaries in the blueprint wording. Methylmalonic acidemia is listed "excluding cobalamin defects" because cobalamin belongs under Cofactors, and glycogenoses are listed "except GSD II" because Pompe disease is handled under Lysosomes. Candidates who study by disease name alone sometimes miss which domain a topic belongs to; studying by the blueprint's own groupings avoids that.
Mid-Weight Content: Carbohydrates, Cofactors, Mitochondria, Laboratory
Carbohydrates (about 10%)
The category covers glycogenoses (excluding GSD II), disorders of glycolysis, gluconeogenesis defects including fructose-1,6-bisphosphatase deficiency, galactose metabolism, fructose metabolism, congenital disorders of glycosylation, and others such as the pentose phosphate pathway. Congenital disorders of glycosylation tend to be the least familiar to candidates trained primarily on newborn-screening conditions.
Cofactors (about 7%)
Cobalamin, biotin, molybdenum, folate, pyridoxine, and biopterin are named individually, with riboflavin, niacin, and thiamine grouped under other. This domain interlocks with others, because a cofactor defect can mimic an organic acidemia or hyperphenylalaninemia. Studying it alongside Amino acids and Organic acids pays off.
Mitochondria (about 7%)
The blueprint separates mitochondrial myopathies by presentation (laboratory findings, Leigh syndrome, adult presentations) from electron transport chain function and assembly, mtDNA mutation disorders, mtDNA maintenance, and mtDNA depletion syndromes. MELAS appears in the other grouping.
Laboratory (about 8%)
This is the category that distinguishes a practicing biochemical genetics laboratorian from a pure clinician. It covers QA/QC, artifact recognition, techniques, and regulations. At roughly 8%, it is heavier than Cofactors or Mitochondria alone, yet it is the category candidates most often treat as an afterthought.
Small Domains That Still Appear
Several categories are individually small, but together they make up a meaningful slice of the exam, and they are often the cheapest points to gain because fewer candidates review them carefully.
- Peroxisomes (about 3%): biogenesis disorders such as Zellweger syndrome, single-enzyme disorders including X-linked adrenoleukodystrophy, and others such as infantile Refsum.
- Purines and pyrimidines (about 3%): Lesch-Nyhan disease and adenosine deaminase deficiency on the purine side, UMP synthase deficiency on the pyrimidine side.
- Transport (about 3%): dibasic aminoaciduria including cystinuria and lysinuric protein intolerance, other amino acid transport disorders, glucose, carnitine, and others.
- Metals (about 3%): copper (Wilson disease, Menkes disease), iron, zinc, and others.
- Neurotransmitters (about 2%): SSADH deficiency, disorders of dopamine synthesis, and others including GABA metabolism.
- Creatine (about 1%) and Other disease category (about 3%).
Because the published percentages are approximate, a 1% category should not be read as "zero or one question." Treat the small categories as brief, targeted review blocks and not as optional.
Exam Timing and Scheduling Mechanics
The next exam is identified as August 2027, and ABMGG's announcement places the 2027 certification exams in the window of August 11 to 14, 2027. Biochemical specialties are offered in odd years, which is the single most important scheduling fact: if you miss a cycle, the wait is long. ABMGG has also approved a transition to an annual certifying examination schedule, so confirm on the board's news page how that change affects the biochemical specialty before you assume the odd-year pattern still governs your plans.
| Item | What the supplied sources establish |
|---|---|
| Issuing body | American Board of Medical Genetics and Genomics (ABMGG) |
| Current blueprint | Biochemical Genetics Blueprint and Content Codes, effective August 2025 |
| Next exam | August 2027 |
| 2027 exam window | August 11-14, 2027 |
| Offering pattern | Biochemical specialties offered in odd years |
| Content structure | Fifteen categories with approximate weights |
For deadlines, application timing, and testing logistics, see the dedicated page on CBG exam dates and scheduling.
What Is Not Published in the Supplied Sources
It is worth being explicit about what this article does not state, because guessing here would mislead you. The supplied official material does not establish the number of questions, the exam timer, the registration fee, or the passing score, so none of those figures appear in this article. If you see a specific number quoted elsewhere, check it against ABMGG directly, and be especially wary of figures that may belong to a different credential sharing the CBG acronym.
The same caution applies to pass-rate and compensation claims. For what is and is not known, read the pages on the CBG passing score, pass-rate data, certification cost, and earnings with the same skepticism you would apply to any secondhand number.
Sequencing Your Preparation Around the Blueprint
The one place where a schedule helps is in ordering the domains so that related material reinforces itself. The sequence below is built around how the blueprint's categories interlock, not around generic study theory. It is a template to adapt, not a prescription, and a full strategy is in the CBG study guide.
Amino acids plus Cofactors
- Build analyte-to-disorder maps for PKU, MSUD, homocystinuria, and urea cycle defects
- Fold in cobalamin, biotin, and biopterin so cofactor mimics are clear from the start
Organic acids plus Carbohydrates
- Drill acylcarnitine and urine organic acid patterns for MMA, PA, IVA, and GA1
- Separate galactose, fructose, glycogenoses, and glycosylation disorders
Lipids plus Mitochondria
- Fatty acid oxidation defects by chain length, then GA2
- Cholesterol disorders and mitochondrial presentation patterns
Lysosomes plus Peroxisomes
- Enzyme, substrate, and phenotype tables for MPS types and sphingolipidoses
- Zellweger spectrum and X-linked adrenoleukodystrophy
Laboratory plus the small domains
- QA/QC, artifact, techniques, and regulations
- Rapid passes through purines, pyrimidines, transport, metals, neurotransmitters, and creatine
Practicing against realistic question formats matters more than rereading notes. The CBG Exam Prep practice test site offers question practice you can map directly back to these blocks, and the CBG cheat sheet is a compact reference for the high-yield facts you will want to revisit near the end.
Key Takeaway
Study by the blueprint's own groupings. When a disorder is explicitly carved out of one category (cobalamin defects from MMA, GSD II from glycogenoses), learn where it lives and learn the cross-over, because that is exactly where integrative questions tend to sit.
Where This Credential Fits in a Career
Biochemical genetics expertise is applied in clinical biochemical genetics laboratories, hospital and academic medical center genetics programs, public health and newborn screening settings, and reference or commercial laboratories that perform metabolic testing. The credential signals readiness to interpret complex metabolic results and to take responsibility for laboratory quality and regulatory compliance, which is why the Laboratory domain is part of the blueprint at all.
Whether it pays off for you depends on your training path and goals. For a structured way to think about that, see the analysis of whether the certification is worth it and the overview of CBG-related jobs. For a sense of how demanding the exam is, read how hard the CBG exam is. Candidates who want structured preparation can also review the page on CBG training.
To start applying all of this to actual questions, the main practice test site is the natural next stop.
Frequently Asked Questions
The American Board of Medical Genetics and Genomics (ABMGG) administers the certification. The authoritative content documents are its blueprint and content outline pages on abmgg.org.
The next exam is identified as August 2027, with ABMGG announcing August 11-14, 2027 for the 2027 certification exams. Biochemical specialties are offered in odd years, so confirm the current schedule on the ABMGG site, especially given the board's approved move toward an annual schedule.
Amino acids is the largest category at about 15%, followed by Lipids at about 13%, then Organic acids and Lysosomes at about 12% each. The percentages are approximate and total 102% because of a discrepancy in the source.
No. Those details were not established from the supplied official sources, so they are intentionally omitted. Check ABMGG directly for current figures instead of relying on secondhand numbers.
No. The categories are exam objectives, not a full curriculum. Pair them with broader reference material, case-based learning, and practice questions, and do not treat the blueprint as a substitute for hands-on laboratory or clinical training.